This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
AHRQ HS 10403-07: CQI in Medicine
The slide presents two charts.
The first chart has two panels. Panel 1 shows use of ß-blocade (n = 107 sites) versus control (n = 101 sites), from Spring 2000 through Spring 2002. During the period studied, the use of ß-blocade increased from just over 60% to about 68%. The control increased from under 58% to almost 66%.
Panel 2 shows use of IMA grafting (n = 101 sites) versus control (n = 101 sites), from Spring 2000 through Spring 2002. During the period studied, the use of IMA grafting increased from around 74% to around 86%. The control increased from 73% to 84%.
A note reads: "In both panels, the first intervention round began in January 2001. In both groups, the intervention resulted in an increase in measure use: this difference vs. contol in this preintervention/postintervention analysis was significant for the ß-blocade group (P = .04)."
Source: Ferguson, TB Jr. JAMA 2004.
The second chart on the slide shows sustainability. A scatterchart shows the percentage of patients receiving betablockers (BB) and a control group. Lines show the trends for both. Both lines rise with a similar curve, but the trend line for the betablock group rises higher than the control. They both begin at 60% at the beginning of the study. The BB trend line is at about 76% after 60 months and the control is at about 70% after 60 months.
Text below charts reads: "Used clinical data systems to establish the infrastructure for continuous quality improvement with process and outcomes data."
Previous Slide Contents Next Slide